Interaction of Pregnane X Receptor with Hypoxia-inducible Factor-1 Regulates Chemoresistance of Prostate Cancer Cells

Overview

Journal Cancer Drug Resist

Date 2023 Jul 17

PMID 37457130

Authors

Jiuhui Wang

Daotai Nie

Affiliations

Soon will be listed here.

Abstract

The nuclear pregnane X receptor (PXR) is a pivotal regulator of steroid and xenobiotics metabolism and plays an important role in shaping tumor cell responses to chemotherapy. Hypoxia within tumor tissue has multifaceted effects, including multiple drug resistance. The goal of this study was to determine whether PXR contributes to hypoxia-induced drug resistance. Metastatic prostate cancer cells were used to study the interaction of PXR and hypoxia-inducible factor-1 (HIF-1 in drug resistance associated with hypoxia. The activities of PXR and HIF-1 were determined by assays for its reporter gene or target gene expression. Co-immunoprecipitation (Co-IP) was used to determine the interaction of PXR and HIF-1. Ablation or inhibition of PXR or HIF-1 was used to determine their roles in hypoxia-induced chemoresistance. PXR was activated by hypoxia, leading to increased expression of multidrug resistance protein 1 (MDR1). Inhibition of PXR by pharmacological compounds or depletion by shRNAs reduced the hypoxic induction of MDR1 and sensitized prostate cancer cells to chemotherapy under hypoxia. HIF-1 was required for PXR activation under hypoxia. Co-immunoprecipitation results showed that HIF-1 and PXR could physically interact with each other, leading to crosstalk between these two transcription factors. PXR contributes to hypoxia-induced drug resistance in prostate cancer cells through its interaction with HIF-1.

References

RYAN H, Poloni M, McNULTY W, Elson D, Gassmann M, Arbeit J . Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res. 2000; 60(15):4010-5. View

Roberts D, Williams K, Cowen R, Barathova M, Eustace A, Brittain-Dissont S . Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells. Br J Cancer. 2009; 101(8):1290-7. PMC: 2768443. DOI: 10.1038/sj.bjc.6605311. View

Chen Y, Tang Y, Chen S, Nie D . Regulation of drug resistance by human pregnane X receptor in breast cancer. Cancer Biol Ther. 2009; 8(13):1265-72. PMC: 3392171. DOI: 10.4161/cbt.8.13.8696. View

Comerford K, Wallace T, Karhausen J, Louis N, Montalto M, Colgan S . Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 2002; 62(12):3387-94. View

Fu B, Xue J, Li Z, Shi X, Jiang B, Fang J . Chrysin inhibits expression of hypoxia-inducible factor-1alpha through reducing hypoxia-inducible factor-1alpha stability and inhibiting its protein synthesis. Mol Cancer Ther. 2007; 6(1):220-6. DOI: 10.1158/1535-7163.MCT-06-0526. View

Teicher B . Hypoxia and drug resistance. Cancer Metastasis Rev. 1994; 13(2):139-68. DOI: 10.1007/BF00689633. View

Jaakkola P, Mole D, Tian Y, Wilson M, Gielbert J, Gaskell S . Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001; 292(5516):468-72. DOI: 10.1126/science.1059796. View

Kim J, Gao P, Dang C . Effects of hypoxia on tumor metabolism. Cancer Metastasis Rev. 2007; 26(2):291-8. DOI: 10.1007/s10555-007-9060-4. View

Wahli W . A gut feeling of the PXR, PPAR and NF-kappaB connection. J Intern Med. 2008; 263(6):613-9. DOI: 10.1111/j.1365-2796.2008.01951.x. View

10.

Jung D, Mangelsdorf D, Meyer U . Pregnane X receptor is a target of farnesoid X receptor. J Biol Chem. 2006; 281(28):19081-91. DOI: 10.1074/jbc.M600116200. View

11.

Synold T, Dussault I, Forman B . The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med. 2001; 7(5):584-90. DOI: 10.1038/87912. View

12.

Kodama S, Koike C, Negishi M, Yamamoto Y . Nuclear receptors CAR and PXR cross talk with FOXO1 to regulate genes that encode drug-metabolizing and gluconeogenic enzymes. Mol Cell Biol. 2004; 24(18):7931-40. PMC: 515037. DOI: 10.1128/MCB.24.18.7931-7940.2004. View

13.

Zhong H, De Marzo A, Laughner E, Lim M, Hilton D, Zagzag D . Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 1999; 59(22):5830-5. View

14.

Chun Y, Choi E, Kim T, Kim M, Park J . A dominant-negative isoform lacking exons 11 and 12 of the human hypoxia-inducible factor-1alpha gene. Biochem J. 2002; 362(Pt 1):71-9. PMC: 1222361. DOI: 10.1042/0264-6021:3620071. View

15.

Chen Y, Tang Y, Guo C, Wang J, Boral D, Nie D . Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters. Biochem Pharmacol. 2012; 83(8):1112-26. PMC: 3339266. DOI: 10.1016/j.bcp.2012.01.030. View

16.

Li J, Shi M, Cao Y, Yuan W, Pang T, Li B . Knockdown of hypoxia-inducible factor-1alpha in breast carcinoma MCF-7 cells results in reduced tumor growth and increased sensitivity to methotrexate. Biochem Biophys Res Commun. 2006; 342(4):1341-51. DOI: 10.1016/j.bbrc.2006.02.094. View

17.

Huang H, Wang H, Sinz M, Zoeckler M, Staudinger J, Redinbo M . Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole. Oncogene. 2006; 26(2):258-68. DOI: 10.1038/sj.onc.1209788. View

18.

Monti E, Gariboldi M . HIF-1 as a target for cancer chemotherapy, chemosensitization and chemoprevention. Curr Mol Pharmacol. 2010; 4(1):62-77. DOI: 10.2174/1874467211104010062. View

19.

Vaupel P, Mayer A . Hypoxia and anemia: effects on tumor biology and treatment resistance. Transfus Clin Biol. 2005; 12(1):5-10. DOI: 10.1016/j.tracli.2004.11.005. View

20.

Chun Y, Choi E, Yeo E, Lee J, Kim M, Park J . A new HIF-1 alpha variant induced by zinc ion suppresses HIF-1-mediated hypoxic responses. J Cell Sci. 2001; 114(Pt 22):4051-61. DOI: 10.1242/jcs.114.22.4051. View